MSN Laboratories has officially introduced Semabest, its domestic semaglutide brand, to the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). The launch is a strategic step toward expanding access to advanced therapies for chronic metabolic diseases.
Product Features and Competitive Edge:
-
Affordability: Semabest is priced nearly 50% lower than the innovator drug, significantly improving financial accessibility for patients.
-
Vertical Integration: The product distinguishes itself through total self-sufficiency, featuring in-house manufactured USDMF-grade API, formulation, and pen devices produced locally in India according to global standards.
-
Administration: The therapy is available as a pre-filled pen for subcutaneous injection.
Clinical Evidence: Phase III clinical studies conducted in direct comparison with the reference drug have confirmed Semabest’s bioequivalence. Results demonstrated comparable reductions in HbA1c levels, fasting and postprandial glucose, and weight loss, while maintaining a safety profile similar to the innovator product.
Market Context: With nearly 90 million people living with diabetes in India, there is a critical need for high-quality yet cost-effective treatment solutions. Leveraging a decade of expertise in complex peptides, MSN Laboratories stated that the launch of Semabest reinforces India’s position in the global supply of next-generation metabolic therapies.
Source: https://vohnetwork.com/news/pharma/msn-labs-launches-semabest-india-made-semaglutide